Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Organogenesis Holdings (ORGO) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Organogenesis Holdings' Gains from Sales and Divestitures rose 1067.23% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 1067.23%. This contributed to the annual value of $1.4 million for FY2024, which is 17452.53% up from last year.
  • Organogenesis Holdings' Gains from Sales and Divestitures amounted to $1.6 million in Q3 2025, which was up 1067.23% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' Gains from Sales and Divestitures peaked at $1.6 million during Q3 2025, and registered a low of $239245.0 during Q2 2022.
  • Moreover, its 4-year median value for Gains from Sales and Divestitures was $949694.0 (2023), whereas its average is $937954.1.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first surged by 23034.84% in 2024, then skyrocketed by 1067.23% in 2025.
  • Quarter analysis of 4 years shows Organogenesis Holdings' Gains from Sales and Divestitures stood at $249106.0 in 2022, then surged by 109.81% to $522651.0 in 2023, then soared by 174.53% to $1.4 million in 2024, then increased by 10.38% to $1.6 million in 2025.
  • Its Gains from Sales and Divestitures was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.6 million in Q1 2025.